Did you mean excedrin ester strength?
Displaying drugs 76 - 100 of 894 in total
Idelalisib
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Armodafinil
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Troglitazone
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) …
Methylprednisone
Methylprednisone has been used in trials studying the treatment of Leukemia, Rheumatoid Arthritis, Renal Transplantation, Kidney Transplantation, and Acute Lymphocytic Leukemia, among others.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Dimethyl sulfoxide
A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during cryopreservation. Dimethyl sulfoxide shows a range of pharmacological activity including...
Approved
Vet approved
Matched Categories: … Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Deferasirox
Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) …
Safinamide
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Categories: … Cytochrome P-450 CYP2A6 Inducers (strength unknown) ... Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP2C8 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inducers (strength unknown) ... Cytochrome P-450 CYP2C19 Inducers (strength unknown) …
Ivosidenib
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP2C8 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Isoniazid
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2E1 Inducers (strength unknown) ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Sulconazole
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Thalidomide
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha...
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) …
Beta carotene
Beta-carotene, with the molecular formula C40H56, belongs to the group of carotenoids consisting of isoprene units. The presence of long chains of conjugated double bonds donates beta-carotene with specific colors. It is the most abundant form of carotenoid and it is a precursor of the vitamin A. Beta-carotene is composed...
Approved
Nutraceutical
Matched Mixtures name: … Vitamin E + 3 (extra Strength) ... Vitamin E + 3 Extra Strength With Zinc …
Ginkgo biloba
Ginkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of ginkgo biloba use the standardized extract of Ginkgo biloba (EGb) 761 (EGb761), which...
Approved
Investigational
Nutraceutical
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Sotagliflozin
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Fosaprepitant
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Approved
Matched Categories: … Cytochrome P-450 CYP2C9 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Progesterone
Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation...
Approved
Vet approved
Matched Categories: … Cytochrome P-450 CYP2A6 Inducers (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) …
Griseofulvin
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Sulfaphenazole
Sulfaphenazole is a sulfonamide antibacterial.
Approved
Matched Categories: … Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Paroxetine
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Human immunoglobulin G
Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population....
Approved
Investigational
Betamethasone phosphate
Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium and water retention. Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.
Approved
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) …
Nafcillin
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Nilotinib
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP2C8 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Displaying drugs 76 - 100 of 894 in total